A newly-created mouse-human embryo contains up to 4% human cells the most human cells yet of any chimera, or an organism made of two different sets of DNA.
Surprisingly, those human cells could learn from the mouse cells and develop faster at the pace of a mouse embryo rather than a more slowly developing human embryo. That finding was "very serendipitous We did not really foresee that," said senior author Jian Feng, a professor in the department of physiology and biophysics at the State University of New York at Buffalo.
Successfully growing human cells in mouse embryos might one day help scientists understand the growth and aging process of our bodies and how diseases such as COVID-19 damage cells and could eventually even serve as a scaffold to grow organs for transplantation, Feng said.
Related: The 9 most interesting transplants
Feng and his team tackled a long-standing issue in creating such chimeras: that in order for human embryonic stem cells and mouse embryonic stem cells to chat and mingle, they needed to be in the same state of development. Embryonic stem cells are pluripotent, meaning they can develop into any type of cell in the body.
But "the human embryonic stem cell looks and behaves very differently from the mouse embryonic stem cell," so past attempts to get them to comingle have all failed, Feng told Live Science. At first, researchers thought the failures were due to some kind of species barrier; but after many years of study, they realized that it wasn't a species issue, but rather a maturity one.
The human stem cells were in a later stage of development called a "primed" state, which normally occurs only after the human embryo has already been implanted in the uterine wall. In contrast, the mouse stem cells were in a more "naive" state, which normally occurs when the mouse embryo is still floating around in the fallopian tubes. In the past, researchers weren't able to convert human cells back to this naive state, Feng said.
In their experiments, Feng and his team were inspired by a process called "embryonic diapause" that occurs in hundreds of mammals from bears to mice: When there's some sort of hardship such as a famine or shortage of water, some animals' embryos can remain in the naive state inside a mother's fallopian tubes for months and sometimes over a year for the environment to become more suitable, Feng said.
It's not clear what triggers the embryos to pause in this state, but a protein called mTOR seems to be a sensor that detects when conditions are bad, he said. Feng and his team figured out that they could target this protein inside human stem cells to make the cells think that they were experiencing famine, and needed to jump to a more naive state where they could conserve energy, Feng said.
The protein mTOR normally promotes the production of proteins and other molecules to support cell growth and proliferation, so by inhibiting it, Feng and his team "shocked" the human cells into changing their metabolism and gene expression. "So it behaves pretty much like the mouse cell," Feng said. What resulted was a naive set of human stem cells that could be cultured together with mouse stem cells and "intermingle very nicely," Feng said. The researchers then injected 10 to 12 of these naive human stem cells into mouse embryos.
In most of the mouse embryos, the naive human stem cells successfully developed into mature human cells in all three germ layers: the ectoderm, or the primary cell layers that develop when the embryo is growing and which later develop to form hair, nails, the epidermis and nerve tissue; the mesoderm, or the cells that make up the organs; and the endoderm, or the inner lining of organs. But no human cells spilled over into germline tissue, which develops into egg and sperm cells.
These germ layers then developed into more differentiated cells, and when the researchers stopped their experiment on the 17th day, 14 embryos were between 0.1% and 4% human (some had less human cells and some had more), with human cells found through the embryo, including in the liver, heart, retina and red blood cells.
Related: First pig-monkey chimeras were just created in China
But what was really "surprising" was the speed at which the human cells developed, Feng said. For example, the embryos were able to generate human red blood cells in 17 days, compared to the roughly 56 days red blood cells take to develop in a growing human embryo. Similarly, human eye cells don't develop until much later on in the embryo, whereas within 17 days, human eye cells including photo receptors formed in the chimera. Basically, the human cells "assumed the clock of the mouse embryo," Feng said. Previously, scientists thought this accelerated development was impossible because the tempo of human cell development was always thought to be "kind of immutable," he added.
This paper identifies a "novel way" of turning primed human pluripotent stem cells into a naive state, said Ronald Parchem, an assistant professor in the Stem Cells and Regenerative Medicine Center at Baylor College of Medicine in Texas, who was not a part of the study. But "the level of chimerism is low in this study," compared to another study that developed chimeras with up to 20% human cells per embryo, he said. That study, however, was published to the preprint database Biorxiv on May 24,and hasn't yet been peer-reviewed. "Together, these studies provide insight into capturing pluripotent states in vitro and highlight the barriers preventing successful cross-species chimerism," Parchem said. "Identifying ways to overcome these barriers has the potential to improve regenerative medicine."
These findings might "stimulate research" in the fundamental understanding of human development, especially how time is measured by biological systems, Feng said. Such chimeras could help scientists understand human diseases. For example, researchers might one day be able to regenerate human blood in a mouse model and study diseases such as malaria. Or if you can create human lung cells, or epithelial cells that line the respiratory tract, that mouse can become a "model system" for studying diseases like COVID-19, Feng said. In other words, mice with human cells can be infected with COVID-19 to understand how the virus attacks the body.
The most cited potential application of such chimeras is organ growth. But this likely won't happen in mice but much larger animals such as pigs, he said. Of course, these applications raise ethical issues, he added. One such ethical consideration is that chimeras blur the lines between species and that makes it difficult to determine the morality or the consciousness that those animals possess. For example, chimeras used in animal testing could be given too many human characteristics and have a similar moral status or consciousness to us, according to a previous Live Science report.
Feng said that much discussion needs to take place before such applications can be considered.
"This field requires much more exploration before this becomes a reality," said Carol Ware, the associate director at the University of Washington's Institute for Stem Cell and Regenerative Medicine, who was also not a part of the study. "A couple of the primary hurdles at this point are determining the host species for these human cells," and public acceptance in the work, she added.
"At this point, it would seem that the speed with which this clinical opportunity will become a reality will not be hindered by the ability to grow human organs," she added. "I would have liked to see," what happens when mTOR is taken away inside the lab dish and these naive human cells are allowed to advance again, particularly to see if some key cellular processes resume again, she added.
The findings were published in the journal Science Advances on May 13.
Originally published on Live Science.
Excerpt from:
New human-mouse chimera is the most human yet - Livescience.com
- Stem Cell Therapy Industry Dynamics and Contributions by RTI - openPR - January 21st, 2025
- Stem Cells Market to Reach USD 44.27 Billion by 2033, Driven by Expanding Applications and Innovations - openPR - January 21st, 2025
- Organoids at the Forefront Innovations in Stem Cell Research and Precision Medicine - openPR - January 21st, 2025
- The promising future of regenerative medicine - Yahoo Finance - January 17th, 2025
- An earful of gill: USC Stem Cell study points to the evolutionary origin of the mammalian outer ear - EurekAlert - January 11th, 2025
- Aspen Partners with Mytos to Automate Stem Cell Production for Parkinsons Therapy - Genetic Engineering & Biotechnology News - January 9th, 2025
- School of Medicine professor receives grant to study improved cancer treatments - Mercer University - January 9th, 2025
- Meet CIRM: the California Institute Pushing Stem Cell and Gene Therapy Research: Part 1 - The Medicine Maker - January 7th, 2025
- Regenerative Medicine Market to Experience Significant Growth, Projected to Reach $183.08 Billion by 2031. - openPR - January 7th, 2025
- Stem-cell therapies that work: 10 Breakthrough Technologies 2025 - MIT Technology Review - January 5th, 2025
- 1st stem cell therapy, new HIV drug approved - ecns - January 5th, 2025
- Science fiction turned reality? Stem cell therapy set to repair child's heart - Ynetnews - January 3rd, 2025
- Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology - The Manila Times - January 1st, 2025
- Allogeneic Stem Cell Transplantation Market Size to Expand Lucratively by 2031 - openPR - January 1st, 2025
- Apoptotic clearance by stem cells: molecular mechanisms for recognition and phagocytosis of dead cells - Nature.com - December 30th, 2024
- Why Medical Tourists are Choosing Mexico: The Affordable Alternative for Advanced Stem Cell Treatments - openPR - December 30th, 2024
- Induced Pluripotent Stem Cells (iPSC) Production Market: Trends, Growth, and the Role of AI - openPR - December 30th, 2024
- Stem cells 'instructed' to form specific tissues and organs - New Atlas - December 28th, 2024
- Stem Cell Transplantation Still the Main Treatment Option for Beta-Thalassemia - Medpage Today - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Galveston County Daily News - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Voice Of Alexandria - December 28th, 2024
- U.S. Stem Cell Therapy Market Revenue to Attain USD 17.70 Bn by 2033 - Precedence Research - December 27th, 2024
- Here are some biggest medical breakthroughs of 2024 - Medical Buyer - December 27th, 2024
- Researchers from Korea University explore how ascorbic acid and FGF4 revolutionize regenerative medicine - EurekAlert - December 27th, 2024
- Regenerative Medicine Market to Skyrocket to USD 73,084.2 Million by 2033 at a 18.5% of CAGR - openPR - December 27th, 2024
- Stem cell therapy to correct heart failure in children could 'transform lives' - Fox News - December 25th, 2024
- Advancing type 1 diabetes therapy: autologous islet transplant breakthrough - Nature.com - December 25th, 2024
- Stem Cell Therapy Market to Triple in Value, Reaching USD 52.1 Billion by 2034 at a 12.1% of CAGR - openPR - December 25th, 2024
- Stem-cell therapies: A breakthrough in treating parkinson's, cancer, diabetes, and more - The Business Standard - December 25th, 2024
- Replay 2024 : 6 Biggest Medical Breakthroughs Of 2024 - NewsX - December 25th, 2024
- Tumbling stem cells? Watch how movement plays a part in their fate - Scope - December 20th, 2024
- SCD patients free of VOEs after treatment with gene-editing therapy - Sickle Cell Disease News - December 20th, 2024
- Japan's Sumitomo to establish regenerative medicine and cell therapy joint venture - BSA bureau - December 20th, 2024
- Brain cells remain healthy after a month on the International Space Station, but mature faster than brain cells on Earth - EurekAlert - December 19th, 2024
- Reindeers Pave the Way for Regenerative Medicine - The Scientist - December 19th, 2024
- Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult... - December 19th, 2024
- What Role Does Regenerative Medicine Play In The Management Of Type 1 And Type 2 Diabetes? - TheHealthSite - December 19th, 2024
- World's 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets - PR Newswire - December 17th, 2024
- Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells - Business Wire - December 17th, 2024
- Stem Cells: Hope on the Horizon for Preterm Babies - Monash University - December 17th, 2024
- Stem Cell Transplant Offers No Difference in OS or PFS in Mantle Cell Lymphoma Compared with Maintenance Therapy Alone - OncoZine - December 17th, 2024
- Inside One Mans Journey with Multiple Myeloma - Men's Health - December 15th, 2024
- Stem Cells Market Size to Reach USD 48.83 Billion By 2034 - Exclusive Report by Precedence Research - BioSpace - December 13th, 2024
- Treating Heart Defects with Tissue-engineered Vascular Conduits - Yale School of Medicine - December 13th, 2024
- Tom Curry: England flanker has stem-cell therapy in bid to make 2027 World Cup - BBC.com - December 13th, 2024
- Stem Cell Manufacturing Market Dynamics Key Drivers Challenges and Technological Innovations - Set to reach USD 26.6 billion by 2033 - PharmiWeb.com - December 13th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of USD 54.7 Bn By 2033, At 12.6% CAGR: Dimension Market Research - The Manila Times - December 13th, 2024
- Stem cell transplantation could save the coral reefs - Ynetnews - December 13th, 2024
- Vitrification Market | Driving Innovations in Cryopreservation for Fertility Treatments and Regenerative - EIN News - December 13th, 2024
- Workshop on Regenerative Medicine concludes at SKUAST-K - Greater Kashmir - December 13th, 2024
- High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma - News-Medical.Net - December 11th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of - GlobeNewswire - December 11th, 2024
- Stem Cell Therapy Market to Worth Over US$ 2,612.92 Million By 2033 | Astute Analytica - GlobeNewswire - December 11th, 2024
- Changes in Blood Cell Production Over the Lifetime | Newswise - Newswise - December 7th, 2024
- Study reveals how stem cells respond to environmental signals, with implications for IBD and colorectal cancer - Medical Xpress - December 5th, 2024
- Stem cell therapy TED-A9 showing safety and early efficacy in trial - Parkinson's News Today - December 5th, 2024
- BMP-2 loaded scaffold for stem and immune cell recruitment in therapeutic applications - News-Medical.Net - December 5th, 2024
- Stem Cell Treatment May Help To Cure Vision Loss - Anti Aging News - December 5th, 2024
- BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024... - December 3rd, 2024
- Stem Cell Therapy Strategic Business Report 2024 - - GlobeNewswire - December 3rd, 2024
- Enhancing the efficacy of cell transplantation therapy for stroke or traumatic brain injury - Medical Xpress - December 1st, 2024
- Apheresis in Cellular Therapies: Unlocking Quality for CAR T and Stem Cell Treatments, Upcoming Webinar Hosted by Xtalks - PR Web - November 29th, 2024
- Stem Cell Therapy Market is expected to Double Its Size by Upcoming Decade - openPR - November 29th, 2024
- AmeraCell Revolutionizes Regenerative Medicine with Accessible and Affordable Stem Cell Clinics - openPR - November 29th, 2024
- Making fat cells skinny: Findings could lead to new, more effective therapies for managing diabetes - Medical Xpress - November 25th, 2024
- Designer Cells Could Be the Key to Autoimmune Disease Treatment - VICE - November 25th, 2024
- Why do athletes store their body cells? - The Times of India - November 22nd, 2024
- What Stem Cell Treatments Canand CantDo - Men's Health - November 22nd, 2024
- Can Regenerative Medicine Speed Up Sports Injury Recovery? Expert Weighs In - Onlymyhealth - November 22nd, 2024
- How Stem Cell Therapy Works for Knee Osteoarthritis: A Cutting-Edge Treatment Explained - Salon Priv Magazine - November 22nd, 2024
- Genting breaks ground on stem cell facility in Bali, Indonesia - theSun - November 22nd, 2024
- A New Stem Cell Therapy for Parkinson's Disease Has Been Confirmed Safe and Effective for the First Time - AccessWire - November 20th, 2024
- More stem cells for sickle cell gene therapy readied with motixafortide - Sickle Cell Disease News - November 20th, 2024
- Isolation and identification of patient-derived liver cancer stem cells and development of personalized treatment strategies - Journal of... - November 20th, 2024
- Stem Cell Therapy Market Expected To Reach 31.33 Billion, - GlobeNewswire - November 18th, 2024
- A look at the broad range of therapies offered sponsored by NeoGenix Stem Cell and Regenerative Therapies - WCNC.com - November 18th, 2024
- Worlds first stem-cell treatment restores vision for patients with severe corneal damage - The Times of India - November 18th, 2024
- MEDEZE Group Wins Industry Champions of the Year at ACES Award, Leads Stem Cell Innovation - Bangkok Post - November 18th, 2024
- Human vision restored by stem cell replacement in regenerative medicine breakthrough - Medical Xpress - November 12th, 2024
- Stem cells grown in space show super powers but theres a catch - Study Finds - November 12th, 2024
Recent Comments